Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment

References

• Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561–566.
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Kantarjian HM, Druker BJ, et al. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med. 2003;138:819–830.
   PubMed Web of Science ®Google Scholar
• Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640–2653.
   PubMed Web of Science ®Google Scholar
• Goldman JM, Melo JV. BCR-ABL in chronic myelogenous leukemia-how does it work? Acta Haematol. 2008;119:212–217.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–927.
   PubMed Web of Science ®Google Scholar
• Kalmanti L, Saussele S, Lauseker M, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015;29:1123–1132.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Kantarjian HM, Jain P, et al. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 2016;122:238–248.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–884.
   PubMed Web of Science ®Google Scholar
• Carlier P, Bernard N, Lagarce L, et al. Pregnancy outcome among partners of male patients receiving imatinib, dasatinib or nilotinib in chronic myeloid leukemia: reports collected by the French network pharmacovigilance centers. Arch Gynecol Obstet. 2017;295:269–271.
   PubMed Web of Science ®Google Scholar
• Abruzzese E, Trawinska MM, de Fabritiis P, et al. Management of pregnant chronic myeloid leukemia patients. Expert Rev Hematol. 2016;9:781–791.
   PubMed Web of Science ®Google Scholar
• Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111:5505–5508.
   PubMed Web of Science ®Google Scholar
• Cole S, Kantarjian H, Ault P, et al. Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature. Clin Lymphoma Myeloma. 2009;9:324–327.
   PubMedGoogle Scholar
• Palani R, Milojkovic D, Apperley JF. Managing pregnancy in chronic myeloid leukemia. Ann Hematol. 2015;94:S167–S176.
   PubMed Web of Science ®Google Scholar
• Berveiller P, Andreoli A, Mir O, et al. A dramatic fetal outcome following transplacental transfer of dasatinib. Anti-Cancer Drugs. 2012;23:754–757.
   PubMed Web of Science ®Google Scholar
• Abruzzese E, Trawinska MM, de Fabritiis P, et al. Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis. 2014;6:e2014028.
   PubMedGoogle Scholar
• Cortes JE, Abruzzese E, Chelysheva E, et al. The impact of dasatinib on pregnancy outcomes. Am J Hematol. 2015;90:1111–1115.
   PubMed Web of Science ®Google Scholar
• Chelysheva E, Turkina A, Polushkina E, Shmakov R. Introduction of a treatment approach for chronic myeloid leukemia and pregnancy considering leukemic burden and pregnancy terms. Blood. 2015;126:5144 (abstract 5144).
   Web of Science ®Google Scholar
• Iqbal J, Ali Z, Khan AU, et al. Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country. Leuk Lymphoma. 2014;55:2109–2113.
   PubMed Web of Science ®Google Scholar
• Alizadeh H, Jaafar H, Rajnics P, et al. Outcome of pregnancy in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors: short report from a single centre. Leuk Res. 2015;39:47–51.
   PubMed Web of Science ®Google Scholar
• Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet. 2004;43:487–514.
   PubMed Web of Science ®Google Scholar
• Myllynen P, Pasanen M, Vähäkangas K. The fate and effects of xenobiotics in human placenta. Expert Opin Drug Metab Toxicol. 2007;3:331–346.
   PubMed Web of Science ®Google Scholar
• Pacifici GM, Nottoli R. Placental transfer of drugs administered to the mother. Clin Pharmacokinet. 1995;28:235–269.
   PubMed Web of Science ®Google Scholar
• Ali R, Ozkalemkas F, Kimya Y, et al. Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet. 2009;280:169–175.
   PubMed Web of Science ®Google Scholar
• Russel MA, Carpenter MW, Akhtar MS, et al. Imatinib mesylate and metabolite concentration in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol. 2007;27:241–243.
   PubMed Web of Science ®Google Scholar
• Giaginis C, Zira A, Theocharis S, Tsantili-Kakoulidou A. Simple physicochemical properties as effective filters for risk estimation of drug transport across the human placental barrier. Rev Clin Pharmacol Pharmacokinet Int Ed 2008;22:146–148.
   Google Scholar
• Hewitt M, Madden JC, Rowe PH, et al. Structure-based modelling in reproductive toxicology: (Q)SARs for the placental barrier. SAR QSAR Environ Res. 2007;18:57–76.
   PubMed Web of Science ®Google Scholar
• Giaginis C, Zira A, Theocharis S, et al. Application of quantitative structure–activity relationships for modeling drug and chemical transport across the human placenta barrier: a multivariate data analysis approach. J Appl Toxicol. 2009;29:724–733.
   PubMed Web of Science ®Google Scholar
• Mohajeri E, Kalantari-Khandani B, Pardakhty A, et al. Comparative pharmacokinetic evaluation and bioequivalence study of three different formulations of Imatinib Mesylate in CML patients. Int J Hematol Oncol Stem Cell Res. 2015;9:165–172.
   PubMedGoogle Scholar
• Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review, Application number 22-068; 2007. p. 26. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022068-s000_ClinPharmR.pdf.
   Google Scholar
• Larson RA, Yin QQ, Hochhaus A, et al. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph + chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol. 2012;68:723–733.
   PubMed Web of Science ®Google Scholar
• Jovelet C, Seck A, Mir O, et al. Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model. Ann Oncol. 2015;26:1500–1504.
   PubMed Web of Science ®Google Scholar
• Vahakangas K, Myllynen P. Drug transporters in the human blood-placental barrier. Br J Pharmacol. 2009;158:665–678.
   PubMed Web of Science ®Google Scholar
• Frederiksen MC. Physiologic changes in pregnancy and their effect on drug disposition. Semin Perinatol. 2001;25:120–123.
   PubMed Web of Science ®Google Scholar
• Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet. 1997;33:328–343.
   PubMed Web of Science ®Google Scholar
• Giaginis C, Theocharis S, Tsantili-Kakoulidou A. Current toxicological aspects ondrug and chemical transport and metabolism across the human placental barrier. Expert Opin Drug Metab Toxicol. 2012;8:1263–1275.
   PubMed Web of Science ®Google Scholar
• Saussele S, Richter J, Hochhaus A, et al. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 2016;30:1638–1647.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–1357.
   PubMed Web of Science ®Google Scholar
• Rea D, Nicolini F, Tulliez M, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI Study. Blood. 2017;129:846–854.
   PubMed Web of Science ®Google Scholar
• Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515–522.
   PubMed Web of Science ®Google Scholar
• Law AD, Dong Hwan Kim D, Lipton JH. Pregnancy: part of life in chronic myelogenous leukemia. Leuk Lymphoma. 2017;58:280–287.
   PubMed Web of Science ®Google Scholar